view original post

NovoCure Limited (NASDAQ:NVCR)’s traded shares stood at 0.65 million during the last session, with the company’s beta value hitting 0.93. At the close of trading, the stock’s price was $103.51, to imply a decrease of -4.79% or -$5.21 in intraday trading. The NVCR share’s 52-week high remains $232.76, putting it -124.87% down since that peak but still an impressive 3.39% since price per share fell to its 52-week low of $100.00. The company has a valuation of $10.43B, with an average of 0.7 million shares in intraday trading volume over the past 10 days and average of 488.18K shares over the past 3 months.

Analysts have given a consensus recommendation of a Hold for NovoCure Limited (NVCR), translating to a mean rating of 3.10. Of 9 analyst(s) looking at the stock, 2 analyst(s) give NVCR a Sell rating. 0 of those analysts rate the stock as Overweight while 5 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.07.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


After registering a -4.79% downside in the last session, NovoCure Limited (NVCR) has traded red over the past five days. The stock hit a weekly high of 116.56 this Friday, 11/19/21, dropping -4.79% in its intraday price action. The 5-day price performance for the stock is -10.04%, and -15.15% over 30 days. With these gigs, the year-to-date price performance is -40.18%. Short interest in NovoCure Limited (NASDAQ:NVCR) saw shorts transact 5.08 million shares and set a 6.84 days time to cover.

Analysts on Wall Street suggest a consensus price target of $152.75, implying an increase of 32.24% to the stock’s current value. The extremes give us $85.00 and $300.00 for target low and target high price respectively. As such, NVCR has been trading -189.83% off suggested target high and 17.88% from its likely low.

NovoCure Limited (NVCR) estimates and forecasts

Revenue is forecast to shrink -177.80% this quarter before falling -250.00% for the next one. The rating firms project that company’s revenue will grow 13.00% compared to the previous financial year.

Revenue forecast for the current quarter as set by 9 analysts is $141.76 million. Meanwhile, for the quarter ending Dec 2021, a total of 9 analyst(s) estimate revenue growth to $147.03 million.Earnings reports from the last fiscal year show that sales brought in $132.66 million and $143.95 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 6.90% before jumping 2.10% in the following quarter.

NVCR Dividends

NovoCure Limited has its next earnings report out between October 27 and November 01. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. NovoCure Limited has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.

NovoCure Limited (NASDAQ:NVCR)’s Major holders

NovoCure Limited insiders hold 13.40% of total outstanding shares, with institutional holders owning 75.97% of the shares at 87.72% float percentage. In total, 75.97% institutions holds shares in the company, led by Capital International Investors. As of Mar 30, 2021, the company held over 9.12 million shares (or 8.82% of shares), all amounting to roughly $1.21 billion.

The next major institution holding the largest number of shares is FMR, LLC with 9.09 million shares, or about 8.79% of shares outstanding. As of the market price on Mar 30, 2021, these shares were worth $1.2 billion.

>> 7 Top Picks for the Post-Pandemic Economy <<

We also have Growth Fund Of America Inc and Smallcap World Fund as the top two Mutual Funds with the largest holdings of the NovoCure Limited (NVCR) shares. Going by data provided on Mar 30, 2021, Growth Fund Of America Inc holds roughly 7.94 million shares. This is just over 7.68% of the total shares, with a market valuation of $1.05 billion. Data from the same date shows that the other fund manager holds a little less at 3.62 million, or 3.50% of the shares, all valued at about 478.7 million.